Evidence map›Paper›PMID 33064882›Full record

ArticlePigment cell & melanoma research2021

Recurrent co-alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis.

Maurizio Fazio, Ellen van Rooijen, Jeffrey K Mito, Rodsy Modhurima, Erika Weiskopf, Song Yang, Leonard I Zon

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pigment cell & melanoma research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Maurizio FazioStem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0083-6601
Ellen van RooijenStem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jeffrey K MitoStem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Rodsy ModhurimaStem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Erika WeiskopfStem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Song YangStem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Leonard I ZonStem Cell Program and the Division of Pediatric Hematology/Oncology, Howard Hughes Medical Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0860-926X
Boston Children's Hospital · USBrigham and Women's Hospital · US

Funding

Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2013 to 2026
$25.3M
VASCULAR, PULMONARY AND RENAL INJURYT32HL007627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIMBRONE, MICHAEL A, MITCHELL, RICHARD N · 1985 to 2019
$12.7M
Cancer Biology in the ZebrafishR01CA103846 · NCI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 2003 to 2022
$7.5M
NCI NIH HHS P01 CA163222NCI NIH HHS R01 CA103846NHLBI NIH HHS T32 HL007627
6 · The paper itself

Abstract

A progressive increase in copy number variation (CNV) characterizes the natural history of cutaneous melanoma progression toward later disease stages, but our understanding of genetic drivers underlying chromosomal arm-level CNVs remains limited. To identify candidate progression drivers, we mined the TCGA SKCM dataset and identified HDGF as a recurrently amplified gene whose high mRNA expression correlates with poor patient survival. Using melanocyte-specific overexpression in the zebrafish BRAF

Indexed as

MutationAnimalsBiomarkers, TumorChromosomes, Human, Pair 1Follow-Up StudiesGene Expression Regulation, NeoplasticHistone-Lysine N-MethyltransferaseHumansIntercellular Signaling Peptides and ProteinsMelanomaPrognosisProto-Oncogene Proteins B-rafSkin NeoplasmsSurvival RateZebrafishBiomarkers, TumorBRAF protein, humanhepatoma-derived growth factorHistone-Lysine N-MethyltransferaseIntercellular Signaling Peptides and ProteinsProto-Oncogene Proteins B-rafSETDB1 protein, human

Identifiers

PMID33064882
PMCPMC8050117
OpenAlexW3093064695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.